Focus On Clinical Trial Review Process In China Before Timeline Reform – Merck Exec
This article was originally published in PharmAsia News
Executive Summary
WASHINGTON - Companies pushing to shorten the clinical trial approval timeline in China should instead focus first on promoting education to improve the review process, according to Merck Clinical Research Operations-Asia Pacific Director Zili Li, who also heads the company's China regulatory policy